Skip to Content

Bristol-Myers Squibb Co BMY

Morningstar Rating
$48.99 −0.15 (0.31%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

BMY is trading at a 22% discount.
Price
$49.14
Fair Value
$79.00
Uncertainty
Medium
1-Star Price
$72.96
5-Star Price
$93.90
Economic Moat
Xzhxz
Capital Allocation
Bfnbjnggf

Bulls Say, Bears Say

Bulls

Bristol is launching several new cancer and immunology drugs that can have high sales trajectories, given the high unmet medical need.

Bears

The acquisition of Celgene brought generic competition for cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BMY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$49.14
Day Range
$48.9649.47
52-Week Range
$47.5870.94
Bid/Ask
$48.98 / $49.06
Market Cap
$99.29 Bil
Volume/Avg
9.2 Mil / 15.5 Mil

Key Statistics

Price/Earnings (Normalized)
6.58
Price/Sales
2.27
Dividend Yield (Trailing)
4.76%
Dividend Yield (Forward)
4.88%
Total Yield
9.98%

Company Profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
34,100

Competitors

Valuation

Metric
BMY
GSK
LLY
Price/Earnings (Normalized)
6.5810.1887.16
Price/Book Value
3.374.5964.46
Price/Sales
2.272.1419.36
Price/Cash Flow
6.4710.2090.55
Price/Earnings
BMY
GSK
LLY

Financial Strength

Metric
BMY
GSK
LLY
Quick Ratio
1.240.590.52
Current Ratio
1.430.880.94
Interest Coverage
8.249.3014.13
Quick Ratio
BMY
GSK
LLY

Profitability

Metric
BMY
GSK
LLY
Return on Assets (Normalized)
16.56%10.54%10.22%
Return on Equity (Normalized)
50.88%50.48%52.03%
Return on Invested Capital (Normalized)
23.63%21.33%19.27%
Return on Assets
BMY
GSK
LLY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoHsshvmfdjGlqz$695.3 Bil
JNJ
Johnson & JohnsonWjzmsqyZtgxg$359.3 Bil
MRK
Merck & Co IncLdtxbbykHnry$321.5 Bil
ABBV
AbbVie IncZdfsptckGccy$297.3 Bil
AZN
AstraZeneca PLC ADRMhkczcflqTtkd$215.8 Bil
RHHBY
Roche Holding AG ADRYvrzspbgsyXccxz$199.7 Bil
NVS
Novartis AG ADRQsjhvjcbRpn$196.0 Bil
PFE
Pfizer IncThbjcbbfLhhc$148.7 Bil
AMGN
Amgen IncKgxzybcmdKtnj$145.8 Bil
SNY
Sanofi SA ADRJhmphdfVyrx$117.3 Bil

Sponsor Center